Neuphoria Therapeutics to be acquired by Scancell Holdings in all-stock merger with CVRs

Neuphoria Therapeutics Inc.

Neuphoria shareholders to receive Parent ADSs and contingent value rights; expected to own ~11.1% of combined company.
Scancell shareholders to own ~64.9%; PIPE investors to own ~17.3% with $38.6M gross proceeds at $0.1205/ADS.
Closing conditions include stockholder approvals, Nasdaq listing of Parent ADSs, and at least $75M in PIPE proceeds.
CVRs entitle holders to 100% of net proceeds from Merck collaboration, Pfizer/KAT6 license, and R&D tax credit over 15 years.
UK Placing of ~$12M and Retail Offer up to $3M also announced; not conditional on merger completion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.